Quantcast
Home > Quotes > XFOR

X4 Pharmaceuticals, Inc. Common Stock (XFOR) Quote & Summary Data

XFOR 
$20.07
*  
0.23
1.13%
Get XFOR Alerts
*Delayed - data as of Apr. 25, 2019 9:47 ET  -  Find a broker to begin trading XFOR now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    XFOR Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 19.08 / $ 20
1 Year Target
11.997
Today's High / Low
$ 20.07 / $ 20.07
Share Volume
282
50 Day Avg. Daily Volume
27,652
Previous Close
$ 20.30
52 Week High / Low
$ 134.5854 / $ 6.9003
Market Cap
134,864,058
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0

Special Dividend Data

Special Dividend
N/A
Special Dividend Date
Mar. 14, 2019
Special Dividend Payment Date
N/A

Intraday Chart

Shares Traded

Share Volume:
282
50 Day Avg. Daily Volume:
27,652

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
Earnings Per Share (EPS):
$ -24.18

Trading Range

The current last sale of $20.07 is 190.86% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 20.07 $ 134.5854
 Low: $ 20.07 $ 6.9003

Company Description (as filed with the SEC)

We are a clinical-stage biopharmaceutical company that has historically focused on applying monoclonal antibody, or mAb, immunotherapies to address serious infectious diseases. We possess a deep understanding of the pathogenesis of infection paired with access to what we believe to be some of the most advanced mAb discovery techniques and platforms available today. Our pipeline is comprised of mAbs targeting multiple serious bacterial and viral pathogens, including Staphylococcus aureus (S. aureus) and respiratory syncytial virus, or RSV. On June 28, 2018, we announced the discontinuation of our Phase 2 clinical trial of ASN100 for the prevention of S. aureus pneumonia in high-risk, mechanically ventilated patients following the completion of a planned interim analysis of unblinded trial data for 118 patients by an independent data review committee, or DRC.  ... More ...  



Risk Grade

Where does XFOR fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 20.07
Open Date:
Apr. 25, 2019
Close Price:
$ 20.30
Close Date:
Apr. 24, 2019


Consensus Recommendation

Analyst Info